Medtronic
 
 

Insertable
Cardiac Monitor

Always on Watch
Reveal® DX Insertable Cardiac Monitor (ICM)

Reveal DX Insertable Cardiac Monitor
Just 9 cc and 15 grams
[+] Click to enlarge

While some causes of unexplained syncope are harmless, others may be serious. The Reveal ICM continuously monitors heart rhythms and can record an ECG at the time of fainting. In fact, infrequent unexplained syncope may be most easily evaluated by an insertable cardiac monitor.1

With continuous monitoring for up to 3 years, Reveal may help confirm or rule out life-threatening arrhythmias as the cause of recurrent but infrequent fainting. Diagnosing and treating a cardiovascular cause of syncope is important to reduce the risk of stroke or sudden cardiac arrest.

Improved Diagnosis – Reveal:

  • May help diagnose where other tests may not have the capabilities to provide answers2,3
  • Is supported by AHA/ACCF and ESC Guidelines*4
  • May direct effective treatment with subsequent reduction in syncopal events5
  • Is labeled MR-Conditional**

Enhanced Sensing and Detection

  • Tracking threshold ensures reliable R-wave sensing†
  • Autoclassification by episode type:
    • Bradycardia
    • Asystole
    • Ventricular tachyarrhythmia
    • Fast ventricular tachyarrhythmia
  • Patient activated with Patient Assistant (symptom-driven)
  • New noise reversion and overrange detection algorithms limit false-positives

Ease of Use from Implant to Follow-up

  • Reveal Vector Check confirms implant positioning
  • Slim, leadless shape simplifies implant
  • Straightforward user interface allows for quick programming and follow-ups
  • Episode log allows data sorting and viewing by rhythm type
  • ECG storage includes prioritization to optimize arrhythmia identification

Long-Term Monitoring Capabilities

  • 3-year monitoring may improve the likelihood of capturing infrequent episodes
  • Provides diagnostic yields much greater than traditional monitoring methods6
  • Lack of wires and patches designed to improve patient compliance

*AHA/ACCF—American Heart Association/American College of Cardiology Foundation ESC—European Society of Cardiology
**Reveal DX has been demonstrated to pose no known hazards in a specified MR environment with specified conditions of use. Please see Reveal DX Clinician Manual for more details.
†Reliable = Sensitivity of 98%, PPV of 99%

References
  1. Krahn A, Klein G, Yee R, et al. Randomized Assessment of Syncope Trial. Conventional diagnostic testing versus a prolonged monitoring strategy. Circulation. 2001;104:46-51.
  2. Deharo J-C, Jego C, Lanteaume A, Djiane P. An implantable loop recorder study of highly symptomatic vasovagal patients. J Am Coll Cardiol. 2006;47:587-593.
  3. Moya A, Brignole M, Menozzi C, et al. International Study on Syncope of Uncertain Etiology (ISSUE) Investigators. Mechanism of syncope in patients with isolated syncope and in patients with tilt-positive syncope. Circulation. 2001. Sept 11;104(11):1261-1267.
  4. Strickberger SA, Benson DW, Biaggioni I, et al. AHA/ACCF Scientific Statement on the Evaluation of Syncope: From the American Heart Association Councils and the American College of Cardiology Foundation: In collaboration with the Heart Rhythm Society. Circulation. January 17, 2006;113(2):316-327.
    Brignole M, Alboni P, Benditt DG, et al. Guidelines on management (diagnosis and treatment) of syncope—update 2004. Europace. November 2004;6(6):467-537.
  5. Farwell  DJ, Freemantle N, Sulke N. The clinical impact of implantable loop recorders in patients with syncope. Eur Heart J. 2006 Feb;27(3):351-6
  6. Krahn A, Klein G, Yee R, Norris C. Final results from a pilot study with an implantable loop recorder to determine the etiology of syncope in patients with negative noninvasive and invasive testing. Am J Cardiol. July 1, 1998;82(1):117-119.

Additional Information